Recursion Pharmaceuticals witnessed a 27% decline in market value over the last week, a period marked by significant Executive and Board changes. The company appointed Dr. Namandjé Bumpus and ...

Recursion Pharmaceuticals is trading at a lower ... gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 ...